A Q&A with Douglas Hoey, CEO of NCPA, on how the new provision from CMS requiring DIR fees at the point of sale is impacting independent pharmacies in 2024.
This week, a divided America watched as the Supreme Court heard oral arguments regarding whether to reinstate restrictions on accessing mifepristone, an essential drug used in medication abortion.
As pharmacy benefit managers gain leverage to continue driving up drug prices, local pharmacies struggle to keep up and Congress has been called to act—but it might be too late.